Browse ANKRD6

Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF12796 Ankyrin repeats (3 copies)
Function

Recruits CKI-epsilon to the beta-catenin degradation complex that consists of AXN1 or AXN2 and GSK3-beta and allows efficient phosphorylation of beta-catenin, thereby inhibiting beta-catenin/Tcf signals.

> Gene Ontology
 
Biological Process GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0007164 establishment of tissue polarity
GO:0007254 JNK cascade
GO:0016055 Wnt signaling pathway
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0031098 stress-activated protein kinase signaling cascade
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0035567 non-canonical Wnt signaling pathway
GO:0043410 positive regulation of MAPK cascade
GO:0046328 regulation of JNK cascade
GO:0046330 positive regulation of JNK cascade
GO:0051403 stress-activated MAPK cascade
GO:0060070 canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090175 regulation of establishment of planar polarity
GO:0198738 cell-cell signaling by wnt
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000050 regulation of non-canonical Wnt signaling pathway
GO:2000052 positive regulation of non-canonical Wnt signaling pathway
GO:2000095 regulation of Wnt signaling pathway, planar cell polarity pathway
GO:2000096 positive regulation of Wnt signaling pathway, planar cell polarity pathway
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ANKRD6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ANKRD6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 0.49; FDR: 0.024300 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ANKRD6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4160.223
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3620.632
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4550.457
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.250.267
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0810.964
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4610.836
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1530.627
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0760.94
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2740.813
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0660.952
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1840.903
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2480.0251
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ANKRD6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ANKRD6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ANKRD6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ANKRD6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ANKRD6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ANKRD6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ANKRD6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolANKRD6
Nameankyrin repeat domain 6
Aliases KIAA0957; diversin; Ankyrin repeat domain-containing protein 6
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ANKRD6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.